Current Studies2018-07-20T17:02:06+00:00

Current Studies

Here at the DSRU, there is a variety of studies currently underway including:

Examples of studies currently underway at the DSRU:

Drug name Brand name Background Study type
Exenatide Bydureon® Bydureon is a prolonged-release suspension for injection indicated for the treatment of type II diabetes in combination with other diabetes medications in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. It was first marketed in the UK in June 2011. M-PEM
Rivaroxaban Xarelto® This study aims to monitor the short term safety and utilisation of rivaroxaban when prescribed by specialists in secondary care for the secondary prevention of atherothrombotic events in adults after acute coronary syndrome (ACS). SCEM (ROSE ACS study)
Dulaglutide Exjade® Dulaglutide is a glucagon-like peptide-1 receptor agonist indicated for the treatment of patients with type 2 diabetes mellitus. The aim of this multi-database post-authorisation safety study (PASS) programme is to assess the safety profile and utilisation of dulaglutide in the European Union. The DSRU is conducting an M-PEM study in England, and it is coordinating a multi-country collaborative research program to address common aims and objectives, using existing data from three European electronic health record databases. M-PEM and European network study
Quadrivalent Live Attenuated Influenza Vaccine Fluenz Tetra The DSRU has conducted annual Enhanced Safety Surveillance (ESS) on Fluenz Tetra, a quadrivalent influenza vaccine, every year since 2014. Vaccine Study
Biologic drugs The DSRU is conducting two similar studies, which look at the extent to which biological medicinal products (‘biologics’) are traceable within the hospital setting and how this may facilitate the reporting of an adverse drug reaction Pharmacist study x2
Impact project This project aims to measure the impact of pharmacovigilance activities by examining the evidence used to support drug withdrawals since the 2012 Pharmacovigilance Legislation and using modelling methods to measure the impact on mortality and morbidity of the withdrawals. The results of the first part of this study are available here. Methodological research under MEPS

Contact Info

Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, U.K.

Phone: +44 (0)23 80 40 86 00

Recent Posts